AVXL:NSD-Anavex Life Sciences Corp (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 22.14

Change

+0.91 (+4.29)%

Market Cap

USD 1.49B

Volume

4.42M

Average Target Price

USD 26.25 (+18.56%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials to treat Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company is based in New York, New York.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-06-18 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

-3.28 (-1.62%)

USD81.30B 135.70 104.16
REGN Regeneron Pharmaceuticals, Inc

+1.91 (+0.36%)

USD57.11B 15.26 11.77
BNTX BioNTech SE

-1.78 (-0.83%)

USD49.23B -99,999.99 35.63
VRTX Vertex Pharmaceuticals Incorpo..

-0.51 (-0.27%)

USD48.76B 17.95 12.38
ALXN Alexion Pharmaceuticals, Inc

+0.72 (+0.40%)

USD39.91B 58.41 42.10
BGNE BeiGene, Ltd

-7.33 (-2.23%)

USD30.29B N/A N/A
GMAB Genmab A/S

-0.61 (-1.40%)

USD29.17B 26.59 3.71
SGEN Seagen Inc

+2.93 (+1.91%)

USD27.46B 42.22 39.29
RPRX Royalty Pharma plc

-0.11 (-0.25%)

USD26.79B 22.60 15.62
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing AVXL

Symbol Name Weight Mer Price(Change) Market Cap
FDM First Trust Dow Jones Sel.. 0.00 % 0.60 %

-0.96 (-1.55%)

USD0.17B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 310.00% 99% A+ 99% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 310.00% 99% A+ 99% A+
Trailing 12 Months  
Capital Gain 361.25% 97% A+ 96% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 361.25% 97% A+ 96% A
Trailing 5 Years  
Capital Gain 450.75% 89% B+ 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 450.75% 89% B+ 91% A-
Average Annual (5 Year Horizon)  
Capital Gain 33.89% 66% D 79% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 33.89% 66% D 79% C+
Risk Return Profile  
Volatility (Standard Deviation) 94.07% 30% F 17% F
Risk Adjusted Return 36.03% 59% F 55% F
Market Capitalization 1.49B 78% C+ 69% D+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 19.46 8% F 7% F
Price / Cash Flow Ratio -69.85 94% A 92% A-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -56.58% 49% F 19% F
Return on Invested Capital -130.29% 11% F 5% F
Return on Assets -31.66% 34% F 10% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 8.37 30% F 14% F
Short Percent 9.66% 34% F 21% F
Beta 0.57 84% B 83% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector